ArticleStem cells translational medicine2026
Extracellular vesicles from SB431542-conditioned human adipose-derived stem cells enhance in vitro and in vivo osteogenesis via a miR-20a-5p-BAMBI-BMP/canonical Wnt signaling axis.
Article in Stem cells translational medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
backgroundCritical-sized bone defects resulting from tumors, trauma, or surgery present a significant clinical challenge due to its poor self-regenerating capabilities and limited therapeutic options. Mesenchymal stem cells (MSCs) have shown promise in bone regeneration, possibly mediated through their secretion of bioactive factors rather than direct engraftment and differentiation. MSC-derived extracellular vesicles (EVs) deliver micro-RNAs (miRs), proteins, and lipids that may modulate bone regeneration.
methodsEVs were isolated by differential ultracentrifugation from osteogenically induced human adipose-derived stem cells (hASCs), treated with or without the small molecule SB431542, an inhibitor of TGFβ signaling (EV-hASCs[-/+]SB). EVs were characterized using western blot and nanoparticle tracking analysis. hASCs were cultured with EV-hASCs[-/+]SBs to assess bone regeneration in vitro. Bone regeneration was assessed in vivo in calvarial defects treated with (EV-hASCs[-/+]SB). EV "cargo" was analyzed for miR-content.
resultsEnhanced osteogenesis is shown in vitro and in vivo upon treatment with EV-hASCs[+]SB. EV-hASCs[+]SB-enriched-miR-20a-5p was identified as a modulating factor in osteogenesis, silencing BAMBI and enhancing early downstream phosphorylation of SMAD1/5 and late activation of β-catenin in hASCs undergoing osteogenic differentiation, targets of bone morphogenetic protein (BMP) and canonical Wnt (cWnt) signaling pathways.
conclusionEVs act as carriers for miR-mediated pro-osteogenic signaling, harnessing the therapeutic potential of MSCs in the context of bone tissue repair.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.